Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Testing effectiveness (Phase 2)UnknownNCT04523402
What this trial is testing

Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis

Who this might be right for
Intrahepatic Cholangiocarcinoma Recurrent
Eastern Hepatobiliary Surgery Hospital 100
Large-scale testing (Phase 3)Active Not RecruitingNCT04669496
What this trial is testing

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Who this might be right for
Intrahepatic CholangiocarcinomaPD1 AntibodyLenvatinib+1 more
Shanghai Zhongshan Hospital 178
Testing effectiveness (Phase 2)Looking for participantsNCT06721286
What this trial is testing

Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)
Tianjin Medical University Cancer Institute and Hospital 70
Testing effectiveness (Phase 2)WithdrawnNCT06017297
What this trial is testing

Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma

Who this might be right for
Borderline Resectable CarcinomaBiliary Tract Cancer
Georgetown University
Testing effectiveness (Phase 2)UnknownNCT04506281
What this trial is testing

PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Who this might be right for
Cholangiocarcinoma, Intrahepatic
Shanghai Zhongshan Hospital 128
Testing effectiveness (Phase 2)Looking for participantsNCT06280508
What this trial is testing

Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

Who this might be right for
Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 40
Testing effectiveness (Phase 2)Looking for participantsNCT05557578
What this trial is testing

GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence

Who this might be right for
Intrahepatic Cholangiocarcinoma
Zhejiang Cancer Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT06208462
What this trial is testing

Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Who this might be right for
Intrahepatic Cholangiocarcinoma
The First Affiliated Hospital with Nanjing Medical University 33
Testing effectiveness (Phase 2)UnknownNCT05672537
What this trial is testing

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

Who this might be right for
DurvalumabIntrahepatic CholangiocarcinomaGemcis
Tianjin Medical University Cancer Institute and Hospital 70